Treatment after VEN+R
In a follow-up analysis of the VEN+R patient cohort, 42 (22%) of 194 patients received subsequent therapy with modalities that included: BTK inhibitor (n=12), BCL-2 inhibitor (n=14), PI3K inhibitor (n=1), CIT (n=14), and other (n=1). 16,17
- Among the 12 patients treated with a BTK inhibitor, 10 patients achieved a response and 2 patients were not evaluable
BTK=Bruton's tyrosine kinase; PI3K=phosphoinositide 3-kinase; CIT=chemoimmunotherapy.
4-year overall survival
MURANO: In a randomized (1:1), multicenter, actively controlled, open-label, phase 3 trial (MURANO), VEN+R was studied against bendamustine in combination with rituximab (BR) in 389 patients with CLL who had received at least one line of prior therapy. The primary endpoint was progression-free survival.
IRC-assessed PFS (primary endpoint)
![81% reduction in risk of progression or death vs BR (HR=0.19; 95% CI: 0.13-0.28 [P<0.0001]). After a median follow-up of 23.4 month (range: 0-37.4+ months): There were 35 events in the VEN+R arm (26 progression and 9 death events) compared with 106 events in the BR arm (91 progression and 15 death events). The median PFS was not reached with VEN+R vs 18.1 months (95% CI: 15.8-22.3) with BR](/content/dam/gene/venclextahcp-fullsite/images/venclexta-cll-rr-81-primary-endpoint-os-desktop.jpg)
48-month post hoc analysis of overall survival 10
The post hoc analysis was not tested for
statistical significance.
- At the time of analysis, the overall survival data were immature. Median overall survival had not been reached in either arm. The rates of death per arm and hazard ratio were unstable and do not reflect the actual overall survival benefit
- The rates of death were 14% (n=28) in the VEN+R arm and 29% (n=57) in the BR arm
